Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
32 Since tirzepatide does not have a GIP (3142) tail, chosen Ala 21 was likely to increase the GLP-1 activity, despite it slightly decreasing the GIP activity
Breastfeeding Mounjaro may pass into your breast milk
372 Allopurinol, categorized as a purine-like XO inhibitor, and febuxostat and topiroxostat, classified as non-purine XO inhibitors, constitute the primary pharmacological approach for ULT
Symptomatic stones that cause pain, inflammation, or complications typically require treatment, which may range from medication management to surgical gallbladder removal (cholecystectomy)
US$ 27.17
US$ 21.87
US$ 25.33
US$ 23.31
US$ 27.56
